By admin 
The PRIMA system is a sophisticated visual prosthesis that combines a subretinal implant with a pair of high-tech glasses and a pocket-sized processor. Unlike previous attempts at retinal implants that were bulky or provided limited resolution, PRIMA is designed to integrate seamlessly with the eye’s remaining neural architecture. The implant itself is a tiny, wireless photovoltaic chip—measuring only 2 millimeters square and 30 microns thick—that is surgically placed underneath the retina. This chip contains 378 independent light-sensing pixels. When the user wears the accompanying glasses, a built-in camera captures the visual environment and transmits that data to a digital projector mounted on the frames. This projector beams infrared light patterns directly onto the chip in the eye, which then converts the light into electrical pulses that stimulate the bipolar cells of the retina. These cells, in turn, send signals through the optic nerve to the brain, where they are interpreted as visual images.
The significance of this technology lies in its targeted application for geographic atrophy. AMD is a leading cause of vision loss globally, particularly among the elderly. In the "dry" form of the disease, the macula—the central part of the retina responsible for sharp, detailed vision—gradually deteriorates. As the photoreceptor cells die off, patients develop a growing "blind spot" or scotoma in the center of their field of vision. While their peripheral vision often remains intact, the loss of central vision makes it nearly impossible to perform tasks that require fine detail, such as reading a book, checking a watch, or identifying the facial expressions of loved ones. Until very recently, there were no approved treatments for GA; while newer drugs like Syfovre and Izervay have been approved to slow the progression of the disease, they cannot restore vision that has already been lost. PRIMA is designed to bridge that gap.
Max Hodak, the CEO of Science Corporation, has famously described the PRIMA system as a "cochlear implant for vision." This comparison is apt. Just as cochlear implants bypass damaged parts of the inner ear to provide a sense of sound to the deaf, the PRIMA system bypasses dead photoreceptors to provide a sense of sight to the blind. The technology does not restore "natural" vision in the traditional sense; rather, it provides a form of prosthetic vision that the brain must learn to interpret. However, clinical data suggests that the brain is remarkably adept at this adaptation.
The European approval, known as the CE Mark, was granted following the successful results of the PRIMAVERA pivotal trial. This study involved 38 patients across Europe who had lost their central vision due to geographic atrophy. The results were nothing short of transformative. On average, patients experienced a significant improvement in visual acuity, with many regaining the ability to read several lines on an eye chart. Specifically, the data showed that many participants could achieve a visual acuity of 20/440 or better, with some reaching even higher levels of clarity through the use of the system’s built-in digital zoom features. In the world of legal blindness, the difference between seeing a blur and being able to distinguish letters is the difference between total dependence and functional autonomy.
Science Corporation’s journey to this milestone is also a story of strategic acquisition and rapid innovation. The PRIMA technology was originally developed by Pixium Vision, a French company that faced significant financial hurdles. When Pixium went into receivership, Science Corporation stepped in to acquire the assets, recognizing the immense potential of the subretinal approach. While other companies, such as the now-defunct Second Sight, focused on epiretinal implants (which sit on top of the retina), the subretinal approach used by PRIMA is widely considered more effective for AMD because it utilizes the eye’s existing signal-processing layers. By acquiring an established technology that had already undergone years of development and clinical testing, Science Corporation was able to bypass the early-stage R&D "valley of death" and move straight toward commercialization.
The competitive landscape for vision restoration is intensifying. While Science Corporation is currently leading the charge for AMD-specific implants, other firms are exploring brain-computer interfaces (BCIs) that bypass the eye entirely. Companies like Neuralink and Cortigent are working on devices that stimulate the visual cortex of the brain. However, these "cortical" implants require invasive neurosurgery and are generally reserved for patients who have lost both eyes or have a damaged optic nerve. For the millions of people with AMD, a retinal implant like PRIMA is a much less invasive and more biologically integrated solution. It keeps the "loop" of vision within the ocular system, allowing the eye to move naturally to scan the environment.
The transition from clinical trials to commercial availability in Europe marks a watershed moment for the medical community. European doctors will now be able to prescribe the PRIMA system to eligible patients, though the rollout is expected to be gradual as surgical centers are trained and reimbursement frameworks are established. In the United States, the path is slightly longer. The Food and Drug Administration (FDA) typically requires its own set of rigorous clinical data, and Science Corporation is currently working toward a U.S. pivotal study. Given the "Breakthrough Device" designation that similar technologies have received, there is hope that the American regulatory process will be expedited, potentially bringing the device to U.S. clinics within the next few years.
Beyond the immediate technical achievement, the PRIMA system raises profound questions about the future of human biology and its integration with machines. As we move closer to "curing" blindness, we are also redefining what it means to see. Patients using the PRIMA system report an experience that is digital in nature—often described as seeing patterns of light that they learn to recognize as shapes and letters. The glasses are equipped with a controller that allows users to adjust contrast and zoom in on objects, effectively giving them "super-vision" capabilities that exceed the natural limitations of the human eye in certain contexts. This blurring of the line between therapy and enhancement is a recurring theme in the work of Max Hodak, whose vision for Science Corporation extends far beyond retinal implants.
The company is also developing "Science Eye," a separate project aimed at treating retinitis pigmentosa (RP) and other forms of total blindness. While PRIMA is a physical hardware implant, Science Eye utilizes an optogenetic approach—using gene therapy to make the remaining cells in the optic nerve light-sensitive, combined with a high-resolution micro-LED display placed on the eye. By pursuing multiple avenues of vision restoration, Science Corporation is positioning itself as a dominant force in the nascent field of "neural engineering."
The economic impact of this technology cannot be ignored. Visual impairment costs the global economy billions of dollars annually in lost productivity and healthcare expenses. By restoring even partial vision to the elderly population, the PRIMA system could significantly reduce the burden on caregivers and allow older adults to remain in their homes longer, maintaining a higher quality of life. However, the cost of the device and the accompanying surgery will likely be high, raising questions about equitable access. Ensuring that this technology is available not just to the wealthy, but to all who need it, will be a major challenge for healthcare systems worldwide.
In conclusion, the unveiling of the PRIMA retinal implant is a beacon of hope for those living in the shadows of macular degeneration. It represents a triumph of interdisciplinary science, merging microelectronics, ophthalmology, and neurology into a single life-changing device. As the first patients in Europe begin to receive their commercial implants, the rest of the world watches closely. The "cochlear implant for vision" is no longer a futuristic concept; it is a clinical reality. While there is still a long road ahead in terms of refining the technology and expanding its reach, the milestone achieved by Science Corporation this week serves as a definitive proof of concept that the era of functional bionic sight has arrived. The blind spot that has defined the lives of so many is finally beginning to clear.
